Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is characterised by neutrophilic airway inflammation and incomplete reversible airflow restriction. Currently, approximately 5--10% adults suffer from COPD worldwide \[[@CR1]\], especially in middle income countries. COPD is also the fourth-leading cause of death causing about 2.75 million deaths annually \[[@CR2]\]. Acute exacerbation of COPD (AECOPD) often leads to dyspnoea, frequent cough, and a significant increase in sputum volume \[[@CR3]\]. An exacerbation can affect the normal course of disease and severely reduce patients' quality of life. Acute exacerbation is also the main cause of hospitalization and death of COPD patients \[[@CR4]\], and one study showed that patients hospitalized with AECOPD who required mechanical respiratory support had a mortality rate of 40% \[[@CR5]\].

The pathogenesis of AECOPD varies and the aetiology includes air pollution, smoking, climate change, and infection. Most AECOPD cases (80%) are caused by infection, of which 40--50% are bacterial; almost all cases involve airway inflammation. The severity of impaired lung function can vary depending on the type of pathogenic bacteria and the degree of infection \[[@CR6]\]. Bronchodilators, mainly beta-2 receptor agonists, anti-cholinergic drugs, and theophylline, are the most commonly used agents in the treatment of AECOPD \[[@CR7]\]. Systemic or inhaled corticosteroids and antimicrobial therapy are also important adjuvant therapies \[[@CR8]\]. Other therapies, such as supplemental oxygen and mechanical ventilation, are also used clinically.

AECOPD quickly progresses from the onset, and the bacterial aetiology is often unclear. Generally, empirical antibiotic therapy is preferred initially when AECOPD patients are hospitalised \[[@CR9]\]. Once the infectious bacteria are identified, specific antibiotics targeting those pathogens are used for treatment. However, at the onset of AECOPD, the physician may not be able to determine whether a patient has a bacterial infection, the type of bacteria, or the severity of infection; therefore, the type of antibiotic to be used for AECOPD treatment remains a matter of debate \[[@CR10], [@CR11]\].

A recent systematic review was performed to describe the therapeutic effect of moxifloxacin on AECOPD and acute exacerbation of chronic bronchitis (AECB). It was found that moxifloxacin is a safe and effective empirical agent for treatment, but this study only included a small number of AECOPD patients \[[@CR12]\]. Another study showed that prophylactic antibiotics could effectively reduce the frequency of exacerbation; however, long-term use might increase bacterial resistance and increase the risk of adverse effects \[[@CR13]\]. Therefore, our research systematically analysed the effect and tolerance of antibiotics for the treatment of patients with AECOPD, and a network meta-analysis was performed to directly and indirectly compare different antibiotics.

Methods {#Sec2}
=======

This network meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews guidelines \[[@CR14]\].

Data search strategy {#Sec3}
--------------------

We systematically searched the PubMed, EmBase, and the Cochrane Central Register of Controlled Trials databases using the following keywords for results published through September 2016 in the English language: chronic obstructive pulmonary disease, COPD, exacerbation, antibiotic, antimicrobial, and random\*. The detail if search strategy in PubMed are presented in Additional file [1](#MOESM1){ref-type="media"}. The references of relevant reviews were also checked to ensure that no relevant studies were omitted.

Data selection and extraction {#Sec4}
-----------------------------

The literature search was undertaken independently by 2 authors and any inconsistencies were settled by group discussion until a consensus was reached. A study was eligible for inclusion if it met the following criteria: 1. it was a randomised controlled trial (RCT); 2. it included patients with exacerbations of COPD but not stable COPD or prophylactic treatment for exacerbations; 3. it investigated a specific antibiotic treatment; 4. one of the outcomes included was the rate of clinical cure (success), microbiological response, relapse of exacerbations, adverse effects, or mortality. The exclusion criteria included the following: 1. it was not a RCT, such as retrospective cohort study; 2. it included another type of disease; 3. it assessed the effects of different usage strategies of only one type of antibiotic; 4. it did not include the desired results. Review articles, conference presentations, secondary research reports, letters, editorials, and basic research articles were also excluded.

We extracted the first author, publication year, country, sample size, gender ratio, experimental intervention, comparison intervention, outcome assessment, and follow-up data. We also assessed the methodological quality of the included trials using a risk of bias approach, as described by the Cochrane Collaboration \[[@CR15]\].

In our analysis, the major efficacy outcome was clinical cure (success) rate and the major tolerance outcome was the rate of adverse effects. Secondary outcomes included microbiological response rate, relapse of exacerbations, and mortality. For the efficacy outcome analysis, we used data with the intention of treating a population comprised of randomized patients who received a study agent.

Statistical analysis {#Sec5}
--------------------

In our analysis, we performed a pairwise meta-analysis using a random-effect model. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to determine the size of the effect for dichotomous outcomes. We also used a random effects network meta-analysis for mixed multiple treatment comparisons \[[@CR16]\]. To rank the treatments for each outcome, we used surface under the cumulative ranking (SUCRA) probabilities \[[@CR17]\]. The clinical cure and adverse effect rates of each treatment are displayed as cluster-ranking plots. Comparison-adjusted funnel plots were used to determine whether small-study effects were present in our analysis \[[@CR18]\]. All tests were two-tailed, and a *P* value of less than 0.05 was considered statistically significant. Data analyses were performed using STATA software (version 13.0; Stata Corporation, College Station, TX, USA).

Results {#Sec6}
=======

Literature search {#Sec7}
-----------------

In our study, 478 articles were identified after duplications were removed. After screening the titles and abstracts, 421 of these articles were excluded. The full-text of the remaining 57 articles were assessed and the following articles were excluded: secondary research studies (9), studies of prophylactic antibiotic therapy (6), studies with no desired outcome (6), studies that included other types of patients (5), studies where the type of antibiotic is unclear (4), studies that included comparison of medication strategies (3), studies without an RCT design (2), conference abstracts (2), and protocols (1). Ultimately, 19 articles, published between 1996 and 2016, that assessed 5906 patients were collected for our systematic review (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}) \[[@CR19]--[@CR37]\]. One of the included trials contained four intervention arms \[[@CR36]\].Fig. 1The PRISMA flowchart illustrates the selection of studies included in our analysis Table 1Characters of included studiesAuthorYearSample sizeRegionMale/femaleExperimental interventionCompareOutcomeFollow-up\#Massimo Giusti \[[@CR19]\]2016258Italy182/76LevofloxacinPrulifloxacinClinical cure rates; Relapse of exacerbation; Mortality1YChin Kook Rhee \[[@CR20]\]2015345Korea312/33ZabofloxacinMoxifloxacinClinical cure rates; Microbiological response; Adverse effects36DMarjolein Brusse-Keizer \[[@CR21]\]201435Netherlands21/14Amoxicillin-clavulanicPlaceboClinical cure rates; Relapse of exacerbation4 MSevim Uzun \[[@CR22]\]201492NetherlandsNAAzithromycinPlaceboAdverse effects12 MHoll Yoon \[[@CR23]\]2013137Korea126/11LevofloxacinCefuroximeClinical cure rates; Microbiological response; Adverse effects14DF.Blasi \[[@CR24]\]2013357Italy222/135PrulifloxacinLevofloxacinClinical cure rate; Microbiological response; Adverse effects6 MCarl Llor \[[@CR25]\]2012310Spain251/59Amoxicillin-clavulanicPlaceboClinical cure rate; Microbiological response; Adverse effects1Y3MRobert Wilson \[[@CR26]\]20121492Multicentre833/659MoxifloxacinAmoxicillin-clavulanicClinical cure rate; Adverse effects8 WSemir Nouira \[[@CR27]\]2010170Tunisia155/15Trimethoprim-sulfamethoxazoleCiprofloxacinClinical cure rate; Adverse effects; Mortality6 MJohannes Daniels \[[@CR28]\]2010223Netherlands133/90DoxycyclinePlaceboClinical cure rate; Microbiological response30DCarl Llor \[[@CR29]\]2009137Spain109/28AmoxicillinAmoxicillin-clavulanicClinical cure rate; Adverse effects30DMara Rubia Andre-Alves \[[@CR30]\]2007102Brazil59/43AzithromycinAmoxicillinClinical cure rate; Adverse effects30DPatrick Petitpretz \[[@CR31]\]2007689France476/109LevofloxacincefuroximeClinical cure rates; Adverse effects6 MH.Lode \[[@CR32]\]2004511Germany277/227LevofloxacinClarithromycinClinical cure rate; Microbiological response; Adverse effects52 WIlknur Basyigit \[[@CR33]\]200430Turkey30/0ClarithromycinPlaceboAdverse effect14DRichard Castaldo \[[@CR34]\]200386U.S38/48DirithromycinAzithromycinClinical cure rate; Adverse effects35DSemir Nouira \[[@CR35]\]200193Tunisia84/9OfloxacinPlaceboClinical cure rate; Adverse effects26DS.Umut \[[@CR36]\]1999106Turkey91/15AzithromycinAmpicillin-sulbactamClinical cure rate10DCiprofloxacinCefaclorL.Allegra \[[@CR37]\]1996733France489/244SparfloxacinAmoxicillin-clavulanicClinical cure rate; Adverse effects24D\#: *D* day, *W* week, *M* Month, *Y* year

Study characteristics {#Sec8}
---------------------

In the included studies, the most common research region was Europe. Studies were also conducted in Asia, North America, and Africa. There were more men than women in the study population, although one study did not mention the ratio of men to women. The following 17 antibiotics were included in our analysis: amoxicillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, azithromycin, cefaclor, cefuroxime, ciprofloxacin, clarithromycin, dirithromycin, doxycycline, levofloxacin, moxifloxacin, ofloxacin, prulifloxacin, sparfloxacin, trimethoprim-sulfamethoxazole, and zabofloxacin. The shortest follow-up time was 10 days and the longest was 1 year 3 months. All the included studies were RCTs and 4 studies were open-label \[[@CR23], [@CR30], [@CR31], [@CR36]\]. Overall, the quality of the studies was ideal (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Graph of the bias risk of each study included

Results of network meta-analysis {#Sec9}
--------------------------------

In the network meta-analysis, the eligible comparisons of clinical cure rates are presented in Fig. [3](#Fig3){ref-type="fig"}, which are predominantly pairwise comparisons of different drug treatments for AECOPD. The figure weighs the nodes according to the number of studies that evaluated each treatment; the edges are weighed according to the precision of the direct estimate, and the edges are coloured based on the average bias level for each pairwise comparison with respect to double-blinding. Of all the comparisons, only azithromycin was directly compared with 5 other active drugs. Amoxicillin-clavulanic acid and ciprofloxacin were directly compared with 4 other drugs including a placebo. For tolerability, the eligible comparisons of adverse effects are presented in Fig. [4](#Fig4){ref-type="fig"}. Only placebo was directly compared with 5 other active drugs, and amoxicillin-clavulanic acid was directly compared with 4 other drugs including placebo.Fig. 3Network of comparisons for the clinical cure rate included in the analysis Fig. 4Network of comparisons for the adverse effects included in the analysis

The league table of the network for clinical cure rate assesses the treatments according to their relative effects and is shown in Additional file [2](#MOESM2){ref-type="media"}: Table S1. In terms of efficacy, ofloxacin was significantly better than both doxycycline (logOR, 2.05; 95% CI, 0.26--3.83) and placebo (logOR, 2.39; 95% CI, 0.95--3.83). Results for the adverse effects are shown in Additional file [3](#MOESM3){ref-type="media"}: Table S2. Dirithromycin was significantly better than moxifloxacin (logOR, −2.15; 95% CI, −3.71-- -0.58), prulifloxacin (logOR, −2.86; 95% CI, −5.39-- -0.33), sparfloxacin (logOR, −1.67; 95% CI, −3.21-- -0.13), and zabofloxacin (logOR, −2.16; 95% CI, −3.88-- -0.44). Placebo was significantly better than moxifloxacin (logOR, 0.99; 95% CI, 0.17--1.81).

The ranking of treatments based on SUCRA probability scores is presented in Fig. [5](#Fig5){ref-type="fig"}. In terms of efficacy, ofloxacin (79.1%) was the most likely to be the best antibiotic in AECOPD treatment followed by ciprofloxacin (70.4%) and trimethoprim-sulfamethoxazole (68.1%). In terms of tolerability, dirithromycin (88.4%) was most likely to be the best drug followed by azithromycin (81.4%) and amoxicillin (68.6%; Fig. [6](#Fig6){ref-type="fig"}). After we performed a comprehensive analysis of the efficacy and tolerability, the cluster ranking showed that dirithromycin had a high clinical cure rate with a low rate of adverse effects. Ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole had high clinical cure rates with median rates of adverse effects (Fig. [7](#Fig7){ref-type="fig"}). There was no publication bias in the comparison-adjusted funnel plot (Additional file [4](#MOESM4){ref-type="media"}: Figure S1).Fig. 5The cumulative ranking plots based on the estimation from SUCRA probabilities of the clinical cure rate Fig. 6The cumulative ranking plots based on the estimation from SUCRA probabilities of adverse effects Fig. 7The clustered ranking plot for clinical cure rates and adverse effects

A traditional meta-analysis was also performed for the microbiological response rate, frequency of recurrence, and mortality. Only the microbiological response rate of doxycycline was significantly better than placebo (OR, 3.84; 95% CI, 1.96--7.54; *P* \< 0.001) (Additional file [5](#MOESM5){ref-type="media"}: Figure S2). There were no other significant results in the frequency of recurrence (Additional file [6](#MOESM6){ref-type="media"}: Figure S3) or mortality rates (Additional file [7](#MOESM7){ref-type="media"}: Figure S4).

Discussion {#Sec10}
==========

In this study, we performed a network meta-analysis to analyse antibiotic treatment in patients with AECOPD. We included several antibiotics in the analysis, including amoxicillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, azithromycin, cefaclor, cefuroxime, ciprofloxacin, clarithromycin, dirithromycin, doxycycline, levofloxacin, moxifloxacin, ofloxacin, prulifloxacin, sparfloxacin, trimethoprim-sulfamethoxazole, and zabofloxacin. We found that dirithromycin had a high clinical cure rate with a low rate of adverse effects. Ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole had high clinical cure rates with median rates of adverse effects. Furthermore, the results of the traditional meta-analysis showed that doxycycline therapy significantly improved microbiological response rates better than placebo; however, there were no significant differences in recurrence or mortality.

The clinical diagnosis of AECOPD relies on manifestations that include a sudden change in the patients' symptoms. Clinical and laboratory tests can rule out other diseases with the same symptoms \[[@CR38]\], however, there is still no single biomarker for the diagnosis and assessment of AECOPD. The most common cause of AECOPD is an upper respiratory infection caused by an increase in the airway bacterial load or the emergence of a new bacterial strain \[[@CR39]\]. In addition, viral infections, air pollution, and some unidentified pathogens can also cause AECOPD \[[@CR40], [@CR41]\]. The main therapeutic strategy is to reduce the severity of an exacerbation, with oxygen therapy and bronchial dilation being the initial treatments \[[@CR42]\]. Glucocorticoids and antibiotics can shorten recovery time, improve lung function and hypoxia, and reduce early recurrence and treatment failure.

Dirithromycin belongs to the macrolide family and has a similar pharmacological activity and clinical efficacy as azithromycin, although it does not use the same metabolic pathway \[[@CR43]\]. Dirithromycin undergoes spontaneous hydrolysis to form erythromycyclamine with the same biological activity, but it does not pass through the hepatic microsomal enzyme system. Dirithromycin is more stable than erythromycin under acidic conditions and has stronger antibacterial action against erythromycin-resistant bacteria. In drug concentration studies in AECOPD patients, dirithromycin had a higher concentration at the site of infection compared with erythromycin on standard application \[[@CR44]\]; this suggests that dirithromycin has a greater ability to prevent bacterial superinfection with viral infection. In addition, dirithromycin did not affect the steady-state pharmacokinetics of theophylline \[[@CR45]\]. In our results, ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole had high clinical cure rates with median rates of adverse effects. Ofloxacin and ciprofloxacin are third generation quinolones and synthetic antibacterial agents that primarily affect bacterial DNA, causing irreversible chromosomal damage \[[@CR46]\]. Ofloxacin and ciprofloxacin act mainly on Gram-negative and Gram-positive bacteria, except for *Staphylococcus aureus,* and have no cross-resistance with other antibiotics; this restricts the efficacy of these drugs in bacterial superinfection after a viral infection. Moreover, a recent systematic review that analysed the effect and safety of moxifloxacin found that it may be a promising and safe alternative for the empirical treatment of AECB and AECOPD \[[@CR12]\]. However, our results showed that moxifloxacin only had a moderate efficacy and lower tolerance compared with the efficacy and tolerance of other drugs. This may be because the comparisons of moxifloxacin versus placebo were based on indirect evidence, and the number of studies correlating the different drugs was not balanced. Trimethoprim-sulfamethoxazole is a sulphonamide and is generally a first-line antibiotic for the treatment of AECOPD; however, with its increased use, drug resistant strains and treatment failure rates have gradually increased \[[@CR47]\]. In addition, the findings of this study suggest that several antibiotics including levofloxacin, moxifloxacin, and clarithromycin have less efficacy and lower tolerance; however, these findings are based on a small number of studies and the comparisons with other drugs were not statistically significant. These results should therefore be verified in future large-scale direct comparison trials. Finally, we noted that the tolerance of placebo was better than other drugs, which might be due to uncontrolled confounders and the nocebo effect.

A previous study suggested that COPD patients who received azithromycin for longer than 1 year had a significantly lower risk of exacerbations and a higher quality of life; however, this regimen also caused hearing loss in a small percentage of patients \[[@CR48]\]. Furthermore, we noted that while antibiotics are effective for patients with AECOPD, they might also increase the risk of adverse effects, including hearing loss and liver, kidney, and nervous system problems. These medications may also cause allergic reactions and anaphylaxis \[[@CR49]\]. In addition, most bacteria in the human body are beneficial, and long-term use of antibiotics will cause dysbacteriosis. The abuse of antibiotics also wastes medical resources, and it accelerates the development of super-resistant bacteria \[[@CR50]\]. Therefore, future large-scale studies should be conducted to explore the optimal duration of antibiotic use in preventing COPD exacerbations.

Many studies have utilized procalcitonin as a biomarker of bacterial infection to guide the use of antibiotics; this is because procalcitonin is released during bacterial infections but not during viral infections or non-infectious inflammation. The result of a systematic review showed that procalcitonin-guided treatment for patients in the intensive care unit allowed for a more judicious use of antibiotics compared with standard therapy \[[@CR51]\]. An RCT showed that there was no difference in the 6-month exacerbation and re-hospitalization rates when the treatments were compared with and without procalcitonin guidance. This study also indicated that three-day antibiotic usage had a good therapeutic effect in patients with low levels of serum procalcitonin \[[@CR52]\]. Therefore, shortening the time of antibiotic use using procalcitonin levels could be very valuable.

Aside from antibiotic therapy, other treatments also have a crucial role in AECOPD treatment. Glucocorticoids can accelerate patient recovery, improve lung function and hypoxia, and reduce treatment failure rates; however, they might not be effective in critically ill patients \[[@CR53]\]. Beta-receptor agonists are the first choice for bronchial dilation, and can improve clinical symptoms and lung function; long-term usage could also reduce the frequency of acute exacerbation and overall mortality. Furthermore, beta-receptor agonists are often combined with inhaled corticosteroids, which yields an even better treatment effect \[[@CR54], [@CR55]\]. In addition, N-acetylcysteine can be used for the treatment of COPD or chronic bronchitis to prevent exacerbations \[[@CR56]\], and tiotropium can significantly reduce the frequency of exacerbations but not hospitalizations \[[@CR57]\].

In the early treatment of patients with AECOPD, empirical antibiotic selection is very important for patient recovery. This network meta-analysis gives us a more comprehensive understanding of the efficacy and tolerability of these drugs; it also allow us to perform indirect comparisons between drugs. Although publication bias did not significantly impact the outcome, it should be noted that different treatment strategies, such as differences in dosages and duration of use, could impact the overall results. Bacterial antibiotic resistance also varies with time and place. Thus, the above factors need to be carefully considered when using antibiotics in the clinical setting. A comparison between traditional and network meta-analysis was not conducted, because the summary results were not consistent. Moreover, traditional meta-analyses only provide direct evidence evaluating the treatment effect of each type of antibiotic compared with placebo, whereas numerous studies provide indirect comparisons of different type of antibiotics.

There are still several limitations of this study. First, our analysis was performed on a study level, not on an individual level. Second, there were few RCTs using a single medication, which may have reduced the reliability of the meta-analysis. Third, there were other factors that could have influenced the results, such as drug dosage and the duration of use. Therefore, more RCTs of antibiotic treatment for AECOPD are needed.

Conclusions {#Sec11}
===========

In conclusion, our study indicated that dirithromycin has a high clinical cure rate with a low rate of adverse effects. Ofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole also have high clinical cure rates with median rates of adverse effects. However, caution should still be exercised when using antibiotics to treat acute exacerbations of COPD.
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